个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Therapeutic Potential for Renal Fibrosis by targeting Smad3-dependent Non-coding RNAs

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Gu Yue-Yu[1,2,3] * ; Liu Xu-Sheng[1,*2] ; Lan Hui-Yao[2,*1] ;
机构： [1]State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong,and Departments of Nephrology and Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. [3]Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
出处：
DOI： 10.1016/j.ymthe.2023.12.009
ISSN：

关键词： Renal fibrosis TGF-β Smad3 non-coding RNAs therapy

摘要：
Renal fibrosis is a characteristic hallmark of chronic kidney disease (CKD) that ultimately results in renal failure, leaving patients with few therapeutic options. TGF-β is a master regulator of renal fibrosis and mediates progressive renal fibrosis via both canonical and non-canonical signaling pathways. In the canonical Smad signaling, Smad3 is a key mediator in tissue fibrosis and mediates renal fibrosis via a number of non-coding RNAs (ncRNAs). In this regard, targeting Smad3-dependent ncRNAs may offer a specific therapy for renal fibrosis. This review highlights the significance and innovation of TGF-β/Smad3-associated ncRNAs as biomarkers and therapeutic targets in renal fibrogenesis. In addition, the underlying mechanisms of these ncRNAs and their future perspectives in the treatment of renal fibrosis are also discussed.Copyright © 2023 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

基金：
National Natural Science Foundation of China (82274276), Research Council of Hong Kong (14117418, 14104019, and 14101121),the High-Level Hospital Construction Project from Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science(KJ012019108), the Guangdong-Hong Kong-Macao-Joint Labs Program from Guangdong Science and Technology Department (2019B121205005), and China Postdoctoral Science Foundation (No.2021M690042, No.2022T150148), the Guangzhou Basic and Applied Basic Research Foundation (No.2023A03J0248), the Talent Support Program of Guangdong Provincial Hospital of Chinese Medicine (No.BJ2022KY03) and the Young Talent Program of Guangdong Academy of Chinese Medical Sciences (No.SZ2022QN07).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 生物工程与应用微生物 1 区 遗传学 1 区 医学：研究与实验
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 生物工程与应用微生物 1 区 遗传学 1 区 医学：研究与实验
JCR分区：
出版当年[2022]版：
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong,and Departments of Nephrology and Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. [3]Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
通讯作者：
通讯机构： [1]State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong,and Departments of Nephrology and Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. [*1]Departments of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China [*2]Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714)：
Gu Yue-Yu,Liu Xu-Sheng,Lan Hui-Yao.Therapeutic Potential for Renal Fibrosis by targeting Smad3-dependent Non-coding RNAs[J].MOLECULAR THERAPY.2024,32(2):313-324.doi:10.1016/j.ymthe.2023.12.009.
APA：
Gu Yue-Yu,Liu Xu-Sheng&Lan Hui-Yao.(2024).Therapeutic Potential for Renal Fibrosis by targeting Smad3-dependent Non-coding RNAs.MOLECULAR THERAPY,32,(2)
MLA：
Gu Yue-Yu,et al."Therapeutic Potential for Renal Fibrosis by targeting Smad3-dependent Non-coding RNAs".MOLECULAR THERAPY 32..2(2024):313-324

相关文献

[1]Estrogen receptor β attenuates renal fibrosis by suppressing the transcriptional activity of Smad3 [2]TGF-β in renal fibrosis: triumphs and challenges [3]Deletion of Smad3 protects against C-reactive protein-induced renal fibrosis and inflammation in obstructive nephropathy. [4]Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease [5]Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. [6]Kidney diseases and long non-coding RNAs in the limelight [7]Introduction of long non-coding RNAs to regulate autophagy-associated therapy resistance in cancer [8]Smad3 Signatures in Renal Inflammation and Fibrosis [9]Endophilin A2 protects against renal fibrosis by targeting TGF-β/Smad signaling [10]The role of non‑coding RNAs in the regulation, diagnosis, prognosis and treatment of osteosarcoma (Review).

资源点击量：2020 今日访问量：0 总访问量：646 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号